How is Medical Affairs Proving its Value?

Life sciences is doubling down on its investment in medical affairs, with mid-sized companies spending an average of $10 million on their global MSL teams – and as much as $48 million for top biopharma.1 However, despite this increasing stature, the industry lacks an effective means to measure the impact of medical’s core competency –

Continue Reading